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The Potential Usefulness of Biological
Markers in Risk Assessment
by Frederica Perera*
Substantial data have been generated during the last 5 years in experimental systems and human
populations which shed light on the potential usefulness of biological markers in human cancer risk
assessment. Following abriefreviewofoverall progresstodate inthebiomonitoring ofhumanpopulations,
this paperturns to the growingbody ofdata regarding carcinogen-DNA and protein adducts as illustrative
markers ofbiologically effective dose ofcarcinogens. The data base illustrates considerable human inter-
individual variation in binding and the presence of significant "background" levels of adducts-both of
which support the absence ofhuman population thresholds for exposure to carcinogens. The contribution
of adduct data to our understanding of the shape of low dose-response curve and the reliability of inter-
species extrapolation, as well as the relevance ofadducts to cancer risk, are also discussed. Even though
adducts can now be useful in hazard identification orqualitative risk assessment, more research is needed
before they can serve as quantitative predictors of human cancer risk.
Introduction
Human cancer risk assessment is conventionally
based on estimates ofadministered dose and/or human
exposure, i.e., the amount ofcarcinogen in the external
environment. Of far greater relevance to risk is the
biologically effective dose or the actual amount of car-
cinogen that has interacted with critical cellular targets
such as DNA, RNA, or protein (1,2). This paper will
summarize progress to date in quantifying biologically
effective dose ofcarcinogens in humans-in particular,
DNAandproteinadducts-inordertoaddresstheques-
tion, "How can these biological markers improve quan-
titative risk assessment?"
Available markers of biologically effective dose
include DNA adducts, protein adducts as a surrogate,
cytogenetic effects [e.g., chromosomal aberrations
(CA), sister chromatid exchange (SCE), and micronu-
clei (MN)], DNA damage and repair [e.g., unscheduled
DNA synthesis (UDS)], and somatic cellmutation [e.g.,
hypoxanthine(guanine)phosphoribosyltransferase
(HPRT) and glycophorin A] (2-4). All are relevant to
the multistage process of chemical carcinogenesis,
which is believed to involve genetic damage at one or
more stages (5-7). Each of these methods has been
applied in at least two human study populations (2,8).
(Table 1). Significant increases in levels ofeach ofthese
biological markers have generally been observed in
exposed individuals compared tobaseline orcontrolval-
ues.
Thereisgeneralagreementthatthesebiomarkerscan
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Table 1. Biological markers in humans.a
Markers Exposure
DNA adducts BP, PAH, cis-DDP,
psoralen, tobacco, N-
nitrosamines, AFB1
Protein adducts
SCE
4-ABP, EtO
Exposed population
Patients, workers,
tobacco users
Smokers, workers
EtO, organic solvents, Workers
pesticides,
herbicides,
chemotherapy agents
Chromosome VC, epichlorohydrin, Workers
aberrations herbicides, EtO,
chemotherapy agents
Micronuclei Organic solvents,
metals
Workers
Unscheduled Propylene oxide, EtO, Workers
DNA synthesis styrene
Mutation Chemotherapy,
radiation
Technicians, patients
Abbreviations: BP, benzo[a]pyrene; PAH, polycyclic aromatic
hydrocarbons; cis-DPP, cisplatinum; AFB1, aflatoxin B1; 4-ABP, 4-
aminobiphenyl; EtO, ethylene oxide; VC, vinyl chloride.
aFor review see (2-4,8).
serve as relevant dosimeters of carcinogens and that
significant increases in biologically effective dose con-
note potentially elevated risk of cancer on the group
level. Thus, the markers constitute early warning sys-
tems to identify carcinogenic hazards orqualitative risk
and can indicate the need forincreased surveillance and
possibly protective measures in the interests of cancer
prevention.F. PERERA
Human Data
Let us turn now to human data regarding DNA and
protein adducts, two promising new markers ofbiolog-
ically effective dose. As dosimeters, protein and DNA
adducts are highly sensitive and can provide valuable
information regarding several different time periods of
exposure: granulocytes and monocytes have lifetimes
on the order of hours to weeks; hemoglobin, 3 to 4
months; andT-celllymphocytes, monthsto years (9,10).
They can also sum up exposures via all routes; e.g.,
inhalation, ingestion, dermal absorption; and in com-
bination with nonchemical-specific makers such as SCEs
and CAs, they can help tease apart the contribution of
individual components of chemical mixtures to which
humans are generally exposed.
Disadvantages are that methods are still semi-exper-
imental; most are not well validated in humans since
studies to date have involved small numbers, and the
relationship between various target tissues and those
available for assay, usually peripheral blood cells or ur-
ine, is yet to be definitively established for most car-
cinogens. In addition, adducts are most relevant to ex-
posures to initiating or mutagenic carcinogens and are
not suitable for dosimetry of carcinogens that act pri-
marily or uniquely during the promotion stage. There
is a major need for biological markers for promoting
agents.
A growing body of data regarding DNA and protein
adducts in human populations with quantifiable expo-
sures to diverse carcinogens illustrates two important
points relevant to quantitative risk assessment (Tables
2 and 3). First, there is significant interindividual var-
iation in binding levels, even when external exposure
is comparable. For example, levels of benzo[a]pyrene-
DNA (BP-DNA) in smokers of 1 to 2 ppd ranged from
nondetectable (ND) to 0.21 fmole adducts/,ug DNA, and
4-aminobiphenyl-hemoglobin (4-ABP-Hb) concentra-
tions ranged from 0.44 to 1.5 pmole/g (11). In cispla-
tinum-treated cancer patients, adduct levels ranged
from ND to 0.4 fmole/,g (15). Significant levels of cis-
platinum-DNA (cis-DPP-DNA) adducts occurred in
only about 50% ofsubjects receiving standardized doses
ofchemotherapy whilethe otherhalfsustained no meas-
urable biological dose (15).
Second, there is a significant background in so-called
"unexposed" controls, e.g., inworkercontrols and nons-
mokers. In all ofthe studies summarized in Table 2, the
mean values forcontrols were significantly greaterthan
zero. In all cases there was overlap in DNA adduct
levels between exposed and control groups. This is not
unexpected giventhe multiple sources ofenvironmental
carcinogens includingpassive smoking, the food supply,
ambient air, etc.
Regarding the low dose-response curve (i.e., expo-
sure-adduct curve) in humans, data are limited, but for
reasons just discussed do not indicate a threshold for
adduct formation by polycylic aromatic hydrocarbons
(PAH), 4-aminobiphenyl (4-ABP), ethylene oxide
(EtO), and tobacco smoke constituents. A reasonably
linear relationhip was seen between estimated EtO ex-
posure and EtO protein in a small number of steriliza-
tion plant workers (17). Similarly, the cumulative dose
of cisplatinum was linearily related to levels of cispla-
tinum-DNA adducts in the individuals who formed
measurable adducts (15).
A recent study of DNA adducts in Finnish iron
foundry workers (n = 35) indicates a dose-response for
benzo[a]pyrene-DNA (BP-DNA) by immunoassay and
a significant increase in adduct levels in exposed indi-
viduals compared to controls (12). Foundry workers
have an increased risk oflung cancer, with highest risk
seen for casters (19). Based upon this and the other
human studies discussed, we can reasonably assume
that these workers with significantly elevated adduct
levels are at higher risk of cancer than groups who have
not received the same high biologically effective dose.
Thus, qualitative judgments about risk are possible for
the group, but not at the individual level.
Implications for Risk Assessment
But now we ask, "How can DNA and protein adducts
improve quantitative riskassessment?" [For a more de-
tailed discussion, see (8)]. Here we are constrained to
consider animal data pertaining to three fundamental
questions: How should we extrapolate from high to low
dose, i.e., what is the shape of the low dose-response
curve? Howreliably can we extrapolate fromlaboratory
Table 2. Examples of studies of adducts in human populations: DNA adducts in peripheral blood cells.
Range,
Marker Exposure Population fmole/>±g Reference
BP-DNA PAH Smokers ND-0.21 (11)
Nonsmokers ND-0.12
Foundry workers ND-2.24 (12)
Controls ND-0.24
06-MedGuo N-Nitrosamines Cancer patients ND-0.16 (13)
Controls ND-0.04
Smoking-related (32p) Cigarette smoke Smokers 0.006-0.04 (14)
Nonsmokers 0.012-0.03
cis-DDP-DNA Cisplatinum Patients ND-0.4 (15)
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Table 3. Examples of studies of adducts in human populations:
Protein adducts in hemoglobin.
Range,
Marker Exposure Population pmole/,ug Reference
4-ABP-Hb Cigarette Smokers 0.44-1.5 (11,16)
smoke
Nonsmokers 0.04-0.3
EtO-Hb EtO Sterilization 400-13,500 (17)
workers
Controls < 50
EtO-Hb EtO Smokers 217-690 (18)
Nonsmokers 27-106
Table 4. Compounds for which proportionality has been
observed between administered dose: Macromolecular binding.
Chemical
Single-dose studies
trans-4-Dimethylaminostilbene
N-Nitrosodimethylamine
Methylating/ethylating agents
EMS
AFB1
4-ABP
DMN
BP
PAH
Sterigmatocystin
Reference
(21)
(21)
(22,23)
(24)
(21)
(22,23)
(25)
(22,23)
(26)
(27)
Chronic or multiple-dose studies
trans-4-Acetylaminostilbene (21)
Methylating/ethylating agents (22)
DEN (22)
2-AAF (22)
NNK (28)
MMS (22,23)
4-ABP (22,23)
AFB1 (22)
EtO (23)
Chloroform (23)
Abbreviations: MMS, methylmethanesulfonate; EMS, ethylmethane-
sulfonate; 2-AAF, 2-acetylaminofluorene; AFB1, aflatoxin B1; DEN,
dietylnitrosamine; NNK, 4(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-
butanone; DMN, dimethylnitrosamine; EtO, ethylene oxide.
animals to humans in calculating risk? What do DNA
and protein adducts tell us about risk of cancer?
Regarding the first question, the convention as re-
affirmed in the EPA Guidelines on Assessment of Can-
cer Risk (20) is to use a multistage model that assumes
additivity onbackground and hence islinearatlowdose.
This model is widely considered to be the most biolog-
ically plausible ofavailable models, but there are many
uncertainties as to the true dose-response relationship,
even in the experimental animal.
There have been a number of attempts to test
whetherlow-dose linearity is avalidassumption by com-
paring administered dose to macromolecular binding in
laboratory animals (Table 4). The first set of studies in
Table 4 gave a single dose (or in one case arepeat dose),
often over a wide range (in one instance 4-5 orders of
magnitude). Generally, exposures were considerably
higher than those encountered by humans, with the
exception ofbenzo[a]pyrene (29). The compounds listed
gave a constant ratio between administered dose and
binding to DNA and/or protein. In the case of formal-
dehyde, however, a nonlinear dose-response for puta-
tive formaldehyde-DNA-protein cross-links was seen in
rats exposed byinhalation duringtwo 6-hr periods (30).
Chronic or multiple dose studies have, with few ex-
ceptions, shown a constant ratio between administered
dose and DNA or protein adducts (Table 4). In addition
to low-dose linearity, a plateau in DNA adduct forma-
tion was generally observed at higher doses ofthe car-
cinogens in Table 4. Only dimethylnitrosamine (DMN)
gave a nonlinear dose response regarding protein ad-
duct formation (23). Thus, single dose and chronic stud-
ies indicate that macromolecular binding is generally
proportional to administered dose, in some cases [such
as BP and 4-(N-methyl-N-nitrosamino)-1(3-pyridyl)-1-
butanone or NNK)], even at levels similar to environ-
mental concentrations.
With respect to interspecies extrapolation ofrisk, the
currently accepted assumption is that humans are as
sensitive asthemost sensitive experimental animal spe-
cies (20,31). Comparative DNAandproteinbindingdata
across species would shed light on the initial question,
"Do humans and test animals receive the same biolog-
ically effective dose ofcarcinogen perunit ofexposure?"
Obvious factors that are likely to affect binding in hu-
mans but not experimental animals include human var-
iability in carcinogen activation, binding, and adduct
repair due to environmental and genetic factors; mul-
tiplicity of exposures both to the chemical of interest
and to other chemicals or agents that are metabolically
activated or cleared via the same pathways orthat bind
to DNA and call upon the same DNA repair systems;
and human exposure to agents that can interact (either
antagonistically orsynergistically) withthechemicalex-
posure of concern to alter binding levels. Thus, even if
binding thresholds or nonlinearities were observed in
animal experiments, they will not necessarily hold for
the diverse human population.
Unfortunately, there is a lack of parallel human and
animal chronic exposure data involving similar levels of
carcinogen and using comparable methods to evaluate
adducts. A serious criticism of the recent attempt to
use observed nonlinearity in putative formaldehyde
DNA-protein cross-links as a basis for risk estimation
(32) was that the animal experiment involving two 6-hr
exposures to formaldehyde is not necessarily relevant
either to the positive cancer bioassay or the human ex-
posure situation.
What do binding levels tell us about quantitative risk
of cancer? Here we must turn to experimental data,
since there have been no prospective human studies
aimed at answering this question.
We might examine this question in two parts: first,
what is the relationship between adducts and induction
of gene mutation; and second, what about the relation-
shipbetween adductsand carcinogenicity? Data arelim-
ited, but in the few studies where the critical adduct
has been identified and measured, there is a good cor-
relation between binding levels and the frequency of
induced mutations (33). Moreover, the ratio of adducts
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to mutations in mammalian cells appears to be about
10:1 for alkylating agents (34) and higher (140-190:1)
for agents (nitrated pyrenes, benzo[a]pyrene) that form
bulky adducts (35,36). These calculations are based on
the assumptions that about 1000 base pairs are involved
inmutation andthatDNAmodification isuniformacross
the genome. They should therefore be interpreted cau-
tiously.
With respecttothe quantitativerelationship between
DNA adducts and carcinogenicity, there are three lines
of evidence: the positive correlation for PAHs and al-
kylating agents between the ability to form covalent
DNA adducts in experimental animals in vivo and their
carcinogenic potency (37,38); in vitro studies quantita-
tively linking the extent of adduct formation to cell
transformation and/or tumor induction (39); and ele-
vated adducts in the target organ of sensitive species
(23). This relationship has not been consistently ob-
served. However, many of these studies have serious
limitations: only short-term DNA adduct persistence
was monitored, and often total adducts, rather than
critical ones, were measured.
A number of factors apparently determine the car-
cinogenic consequence ofDNA adducts, and these must
be reasonably well understood and accounted forbefore
any attempt can be made to derive quantitative risk
estimates based on binding data. These include the rate
of accurate repair prior to replication, levels of critical
adduct occurring at the target site and (ideally) the
concentration ofadducts at vulnerable sites orhot spots
on the genome. Determining factors also include the
subsequent exposure to agents that cause promotion or
progression. Thus, for quantitative risk assessment, at
a minimum, we need to identify the critical persistent
adduct at the target site or an established surrogate.
One well-developed effort to utilize laboratory and
human biomonitoring adduct data to predict risk is that
ofEhrenberg et al. for EtO (40). Here macromolecular
(hemoglobin) bindingwas experimentally determined to
be directly proportional to target tissue dose. Relation-
ships between tissue dose, target, and molecular dose
were experimentally determined, as wasthetissue dose
of EtO that would produce the same number of muta-
tions as a unit ofradiation (or the radiation equivalent
dose of EtO). EtO-histidine adducts were measured in
sterilization plant workers, and the risk of a 1 ppm-hr
of EtO exposure was estimated to be equivalent to 10
mrad ofradiation (17). Theworkers' averagetissuedose
ofEtO was converted to radiation risk equivalents. Ex-
cess cancer risk (leukemia) was predicted, which is sim-
ilar to that seen in follow-up epidemiological studies of
that cohort (41). EtO may be a special case in that it is
a direct-acting and stable electrophile that distributes
uniformly in different tissues.
In summary, this is a challenging and exciting time
for both DNA adduct research and risk assessment. To
fulfill the promise of a partnership between the two
disciplines, we clearly need more parallel chronic ex-
posure data on binding in experimental models and hu-
mansaswellasprospective studies inanimalsandmodel
human populations exposed to the same environmental
carcinogens.
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